anxiety and depression
Conditions
Interventions
Blank Control Group:All participants shall maintain their regular lifestyle throughout the trial
Sponsors
Beijing Normal University
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: (1)Enrolled college students (undergraduates, master's students and doctoral students). (2)Present with mild to moderate anxiety and depressive emotions, meeting at least one of the following five criteria: 1) Hamilton Anxiety Rating Scale (HAMA): score = 7 and 16. (3)Physical Activity Rating Scale-3 (PARS-3): total score = 19. (4)Participants have no intellectual impairment, volunteer to participate and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Having a history of severe mental illnesses such as schizophrenia and bipolar disorder, or suicidal ideation; having received psychotherapy, medication or other interventions for anxiety and depression. (2) Having a history of gastrointestinal surgery within the past year, or suffering from gastrointestinal diseases, malignant tumors, autoimmune diseases, infectious diseases, renal insufficiency or severe nephropathy (serum creatinine > 3.0 mg/dL). (3) Having a history of epilepsy or scalp lesions. (4) Having taken probiotics, antibiotics, anti-inflammatory drugs or psychotropic medications in the past three months. (5) Having practiced Tai Chi regularly in the past three months. (6) Having participated in any exercise intervention trials in the past three months. (7) Having severe contraindications to exercise, including severe cardiopulmonary diseases, osteoarthropathy and motor system injuries.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Anxiety Rating Scale;Generalized Anxiety Disorder 7-item Scale;Hamilton Depression Rating Scale-17;Patient Health Questionnaire-9;Positive and Negative Affect Schedule;Depression Anxiety Stress Scales;Center for Epidemiologic Studies Depression Scale;16S rRNA;Interferon-?;Interleukin-6;Indoleamine 2,3-dioxygenase;Kynurenic acid;Kynurenine;Quinolinic acid;3-Hydroxykynurenine;Tryptophan;3-Indolepropionic acid;Indoleacetic acid;5-Hydroxytryptamine;Vasoactive intestinal peptide;Quinolinic acid;Brain-derived neurotrophic factor;Zonulin; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cortisol;Corticotropin-releasing hormone;Adrenocorticotropic hormone;Gamma-aminobutyric acid;Glutamic acid;5-Hydroxyindoleacetic acid;Indole-3-lactic acid;Cytochrome P450 1A1;Cytochrome P450 1B1;Ionized calcium binding adaptor molecule 1;CD86;CD206;Short-chain fatty acids;Aromatic L-amino acid decarboxylase;Tyrosine decarboxylase;Glutamic acid decarboxylase;Lipopolysaccharide;Lipopolysaccharide binding protein;Matrix metalloproteinase-9;Interleukin-1ß;Interleukin-10;Tumor necrosis factor-a;Farnesoid X receptor;Takeda G protein-coupled receptor 5;Soluble cluster of differentiation 14;Physical Activity Rating Scale-3;Symptom Checklist 90;World Health Organization Quality of Life Scale;International Physical Activity Questionnaire;Mini Nutritional Assessment Short-Form;Perceived Stress Scale-10;Profile of Mood States;Exercise-induced Mood Scale;24-hour dietary recall questionnaire;Food Frequency Questionnaire;General Dietary Behavior Scale;Chinese Adults Dietary Behavior Scale;Chinese Adults Dietary Behavior Scale;Pittsburgh Sleep Quality Index;Near-Infrared Spectroscopy; | — |
Countries
China
Contacts
Public ContactLvshaojun
Beijing Normal University
Outcome results
None listed